Stockscreener 앱 받기
0.00
100.00%
-0.55
Marinus Pharmaceuticals Inc 주식(MRNS)의 최신 뉴스
Shareholders that Lost Money on Marinus Pharmaceuticals, Inc. (MRNS) Should Contact Levi & Korsinsky About Pending Class ActionMRNS - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com - Defense World
Can The RAISE Study Data Give Marinus' Stock A Boost? - RTTNews
FINAL MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Purchases 354,393 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc.(MRNS) Shareholders - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Shareholders - ACCESS Newswire
Kiniksa Pharmaceuticals (NASDAQ:KNSA) versus Marinus Pharmaceuticals (NASDAQ:MRNS) Financial Analysis - Defense World
Fragile X Syndrome Market to Show Remarkable Growth Trends from - openPR.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus - MarketScreener
Marinus pharmaceuticals director sells shares for $864 - MSN
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire - The Globe and Mail
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Refractory Status Epilepticus Treatment Market Size in 7MM - openPR.com
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Developmental and Epileptic Encephalopathies Treatment - openPR.com
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com - Armenian Reporter
MRNS LAWSUIT ALERT: Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNS - ACCESS Newswire
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: - openPR
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals director sells shares worth $869 - MSN
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - MSN
Tuberous Sclerosis Complex Therapeutics Market Size Report - openPR
IMMINENT MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB - Defense World
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock By Investing.com - Investing.com UK
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Marinus Pharmaceuticals, Inc.Common Stock (NQ: MRNS - FinancialContent
0.78%
자본화:
|
볼륨(24시간):